| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
15.86(B) |
| Last
Volume: |
1,605,892 |
Avg
Vol: |
1,353,529 |
| 52
Week Range: |
$92.79 - $209.935 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 12 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$0 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
1,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$314,105 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
4 |
17 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dadswell Charles |
Sr VP & General Counsel |
• • – |
2018-01-29 |
4 |
D |
$241.78 |
$53,192 |
D/D |
(220) |
7,191 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2018-01-29 |
4 |
AS |
$244.18 |
$305,225 |
D/D |
(1,250) |
7,338 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2018-01-29 |
4 |
OE |
$51.17 |
$51,170 |
D/D |
1,000 |
8,588 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2018-01-29 |
4 |
D |
$241.78 |
$63,588 |
D/D |
(263) |
25,944 |
|
- |
|
| Stapley Marc |
EVP Strategy & Corp Developmt |
• • – |
2018-01-29 |
4 |
D |
$241.78 |
$63,588 |
D/D |
(263) |
28,052 |
|
- |
|
| Ronaghi Mostafa |
Sr VP & CTO |
• • – |
2018-01-29 |
4 |
D |
$241.78 |
$52,950 |
D/D |
(219) |
67,891 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2018-01-29 |
4 |
D |
$241.78 |
$71,083 |
D/D |
(294) |
13,481 |
|
- |
|
| Stapley Marc |
EVP Strategy & Corp Developmt |
• • – |
2018-01-17 |
4 |
AS |
$241.67 |
$484,667 |
D/D |
(2,000) |
28,315 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2018-01-16 |
4 |
AS |
$241.69 |
$3,655,763 |
D/D |
(15,000) |
437,899 |
|
- |
|
| Hampton Malcolm Garret |
SVP Clinical Genomics Group |
• • – |
2018-01-09 |
4 |
D |
$242.80 |
$86,922 |
D/D |
(358) |
7,416 |
|
- |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2018-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,542 |
1,542 |
|
- |
|
| Samad Samer Abdul |
Sr. VP and CFO |
• • – |
2018-01-08 |
4 |
D |
$227.06 |
$54,040 |
D/D |
(238) |
3,431 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2018-01-03 |
4 |
AS |
$224.50 |
$32,553 |
D/D |
(145) |
7,411 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2018-01-02 |
4 |
AS |
$222.97 |
$4,468,090 |
D/D |
(20,000) |
452,899 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2017-12-29 |
4 |
AS |
$217.38 |
$271,725 |
D/D |
(1,250) |
7,588 |
|
- |
|
| Epstein Robert S |
Director |
• • – |
2017-12-29 |
4 |
OE |
$51.17 |
$51,170 |
D/D |
1,000 |
8,838 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2017-12-19 |
4 |
AS |
$214.85 |
$4,309,502 |
D/D |
(20,000) |
472,899 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2017-12-18 |
4 |
D |
$217.29 |
$421,108 |
D/D |
(1,938) |
82,532 |
|
- |
|
| Ostadan Omead |
EVP Ops, Products, Strategy |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,920 |
26,207 |
|
- |
|
| Ronaghi Mostafa |
Sr VP & CTO |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,336 |
68,110 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,341 |
492,899 |
|
- |
|
| Dadswell Charles |
Sr VP & General Counsel |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,168 |
7,556 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,102 |
13,775 |
|
- |
|
| Samad Samer Abdul |
Sr. VP and CFO |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,460 |
3,669 |
|
- |
|
| Hampton Malcolm Garret |
EVP Clinical Genomics Group |
• • – |
2017-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,920 |
6,453 |
|
- |
|
1655 Records found
|
|
Page 29 of 67 |
|
|
0.56 (0.51%) 
